Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting
Aptevo Therapeutics will showcase its multispecific antibody platform in a presentation at the SITC 2026 Annual Meeting, held November 4-8 in Phoenix. The presentation (abstract 1060) will highlight the company's CD40-directed multispecific portfolio, which is designed to localize immune activation to the tumor microenvironment by engaging innate and adaptive immunity.
Key figures
- Meeting dates
- November 4-8, 2026
- Abstract number
- 1060
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.